Evidence map›Paper›PMID 38023203›Full record

ArticleFrontiers in oncology2023

Dosimetric comparison in sparing normal tissue dosage by using auto-SBRT planning in oligo liver tumors.

Shu Zhang, Weiyi Zhan, Ni Zeng, Jiangping Yang, Maoqi Xiong, Wenjun Liao, Nianyong Chen, Jianghong Xiao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shu ZhangHead and Neck Oncology Department, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Weiyi ZhanCancer Center, West China Hospital, Sichuan University, Chengdu, China.
Ni ZengHead and Neck Oncology Department, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Jiangping YangHead and Neck Oncology Department, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Maoqi XiongWest China Clinical Skills Training Center, West China School of Medicine/West China Hospital, Sichuan University, Chengdu, China.
Wenjun LiaoDepartment of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Nianyong ChenHead and Neck Oncology Department, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Jianghong XiaoRadiotherapy Physics and Technology Center, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The study aimed to compare the dosimetric distribution of VMAT plans by increasing the number of half arcs in liver SBRT and investigate the effect by using automatic plan software in plan optimization. Method: Thirty-one patients with oligo liver tumors were randomly selected. VMAT treatment plans with different numbers of coplanar half arcs were generated. Result: Adding arcs significantly increased the PTV, Conclusion: In the context of SBRT for oligo liver tumors, increasing the number of coplanar half arcs will improve PTV conformity and offer better protection for OARs, albeit at the expense of increased treatment duration. Considering the trade-off between plan quality and treatment efficiency, a three-arc plan may be more suitable for clinical implementation.

Indexed as

auto-planningdose sparingliver cancernumber of half arcsstereotactic body radiation therapyvolumetric-modulated arc therapy

Identifiers

PMID38023203
PMCPMC10665725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.